recurrent spontaneous abortion
Conditions
Interventions
normal pregnancy (villous and decidual tissues) versus recurrent spontaneous abortion (villous and decidual tissues):Nil
Sponsors
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Eligibility
Sex/Gender
Female
Age
22 Years to 35 Years
Inclusion criteria
Inclusion criteria: First-trimester villous and decidual tissues were obtained from the placentas of individuals with clinically normal pregnancies (age ranged from 22 to 35, 28+/-3 years; gestational age at sampling, 52+/-9 days, mean +/- SD) that had been terminated for non-medical reasons. Villous and decidual samples were also obtained from patients with RSA (age ranged from 22 to 35, 28 +/- 4 years, gestational age at abortion, 53 +/- 7 days) who had experienced more than three unexplained and consecutive spontaneous abortions. The gestational age of RSA patients and first-trimester normal pregnancies were paired.Second-trimester placentas were obtained from individuals with clinically normal pregnancies (age ranged from 22 to 34, 28 +/- 3 years) that had been terminated due to unplanned pregnancy or family planning. Third-trimester placentas were obtained from individuals (age ranged from 24 to 33, 28 +/- 3 years) who had undergone normal vaginal delivery.
Exclusion criteria
Exclusion criteria: Among these patients, we excluded cases with co-existing health problems: 1) Infection, by taking body temperature and blood examination; 2) endocrine or metabolic diseases, including polycystic ovarian syndrome,hyperprolactinemia, hypothyroidism, hyperthyroidism, diabetes mellitus, etc., by testing hormone levels, thyroid function, and blood glucose levels; 3) chromosomal abnormalities, by conducting villi low-density chip to exclude chromosome number abnormalities; 4) anatomical abnormalities, including congenital malformation of uterus, cervical incompetence, intrauterine adhesions, uterine fibroids, adenomyosis, etc.; 5) autoimmune diseases, including anti-phospholipid antibody syndrome, systemic lupus erythematosus, Sjogren's syndrome, etc., by testing immune index.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| metabolite; | — |
Secondary
| Measure | Time frame |
|---|---|
| metabolic enzymes; | — |
Countries
China
Contacts
Public ContactJin LIping
Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine
Outcome results
None listed